Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial.
Yasar B, Suh YE, Chapman E, Nicholls L, Henderson D, Jones C, Morrison K, Wells E, Henderson J, Meehan C, Sohaib A, Taylor H, Tree A, van As N. Yasar B, et al. Among authors: henderson d, henderson j. Int J Radiat Oncol Biol Phys. 2024 Mar 16:S0360-3016(24)00425-5. doi: 10.1016/j.ijrobp.2024.03.009. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 38499253 Free article.
Stereotactic body radiotherapy for prostate cancer.
Henderson DR, Tree AC, van As NJ. Henderson DR, et al. Clin Oncol (R Coll Radiol). 2015 May;27(5):270-9. doi: 10.1016/j.clon.2015.01.011. Epub 2015 Feb 21. Clin Oncol (R Coll Radiol). 2015. PMID: 25707911 Review.
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Brand DH, et al. Among authors: henderson d. Lancet Oncol. 2019 Nov;20(11):1531-1543. doi: 10.1016/S1470-2045(19)30569-8. Epub 2019 Sep 17. Lancet Oncol. 2019. PMID: 31540791 Free PMC article. Clinical Trial.
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Among authors: henderson d. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Free article. Clinical Trial.
Reply from Authors re: Tillmann Loch, Pat Fox Fulgham. Active Surveillance Challenges in Men with Prostate Cancer: Role of Imaging Today and Tomorrow. Eur Urol 2016;69:1034-6: Imaging in Active Surveillance for Prostate Cancer: Where Should We Focus Our Research?
Henderson DR, de Souza NM, Parker CC, van As NJ. Henderson DR, et al. Eur Urol. 2016 Jun;69(6):1037. doi: 10.1016/j.eururo.2015.11.027. Epub 2015 Dec 11. Eur Urol. 2016. PMID: 26691314 No abstract available.
2,169 results